Recent Investment Analysts’ Ratings Updates for Urogen Pharma (URGN)

Urogen Pharma (NASDAQ: URGN) recently received a number of ratings updates from brokerages and research firms:

  • 11/15/2017 – Urogen Pharma was downgraded by analysts at UBS AG from an “outperform” rating to a “market perform” rating.
  • 11/15/2017 – Urogen Pharma was downgraded by analysts at Raymond James Financial, Inc. from an “outperform” rating to a “market perform” rating.
  • 11/15/2017 – Urogen Pharma had its “outperform” rating reaffirmed by analysts at CIBC. They now have a $51.00 price target on the stock, up previously from $32.00.
  • 11/15/2017 – Urogen Pharma had its “buy” rating reaffirmed by analysts at Cowen and Company. They wrote, “URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18).””
  • 11/14/2017 – Urogen Pharma was given a new $51.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an “outperform” rating on the stock.
  • 10/18/2017 – Urogen Pharma was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “
  • 10/9/2017 – Urogen Pharma had its price target raised by analysts at Jefferies Group LLC from $27.00 to $37.00. They now have a “buy” rating on the stock.

Shares of Urogen Pharma (NASDAQ:URGN) opened at $41.80 on Tuesday. Urogen Pharma has a one year low of $13.01 and a one year high of $44.63.

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

What are top analysts saying about Urogen Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Urogen Pharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit